

Adult Cancers	
Breast (18 trials)	Page 1-2
Cutaneous (5 trials)	Page 2-3
Gastrointestinal (17 trials)	Pages 3-5
Genitourinary (19 trials)	Pages 5-8
Gynecological (4 trials)	Page 8-9
Head and Neck (11 trials)	Page 9-10
Malignant Hematology (13 trials)	Page 10-11
Melanoma (0 trial)	
Multiple/III-Defined Disease Sites (11 trials)	Page 11-12
Neurologic Oncology (3 trials)	Page 12-12
Thoracic (7 trials)	Page 13-13
Other Trials (165 trials)	Pages 14-23
Total Trials = 225	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Breast > Prevention					
15754	NCT02950480	Munster, Pamela	Breast Capsular Contracture following Post-Mastectomy Reconstruction in Women Treated with the Leukotriene Inhibitor Zafirlukast: A Phase II Trial	Treatment	Kerry Inokuchi; Kerry.Inokuchi@UCSF.EDU;
> Breast > Breast Cancer Treatment > Early Stage Breast Cancer					
15753	NCT02400476	Chien, Jo	An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis	Supportive Care	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
ALLIANCE-A011401	NCT02750826	Melisko, Michelle	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
16757	NCT02513394	Rugo, Hope	A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
167514	NCT03094052	Chien, Jo	An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab and Neratinib followed by Neratinib Monotherapy, and Intensive Anti-diarrhea Prophylaxis	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
16704	NCT02872025	Esserman, Laura	Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288 Ivy Wong; Ivy.Wong@ucsf.edu; +1 415-353-7873
> Breast > Breast Cancer Treatment > Surgery					
15754	NCT02950480	Munster, Pamela	Breast Capsular Contracture following Post-Mastectomy Reconstruction in Women Treated with the Leukotriene Inhibitor Zafirlukast: A Phase II Trial	Treatment	Kerry Inokuchi; Kerry.Inokuchi@UCSF.EDU;
> Breast > Breast Cancer Treatment > Advanced Breast Cancer > ER+					
11996	NCT01554371	Rugo, Hope	A Phase 1b/II Study of Eribulin in Combination with Cyclophosphamide in Patients with Solid Tumor Malignancies	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
177525	NCT03056755	Rugo, Hope	A Phase II, Multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK4/6 inhibitor treatment	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
147522	NCT02384239	Rugo, Hope	Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
> Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+					
157515	NCT02492711	Rugo, Hope	A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
167510	NCT02614794	Chien, Jo	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
> Breast > Breast Cancer Treatment > Advanced Breast Cancer > Triple Negative					
11996	NCT01554371	Rugo, Hope	A Phase 1b/II Study of Eribulin in Combination with Cyclophosphamide in Patients with Solid Tumor Malignancies	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
16706	NCT02628535	Fong, Lawrence	A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
147523	NCT02395627	Munster, Pamela	Reversing Therapy Resistance with Epigenetic-Immune Modification (Pembrolizumab, Vorinostat, Tamoxifen)	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
> Breast > Breast Cancer Treatment > Advanced Breast Cancer > Brain Metastases/leptomeningeal dz					
17752	NCT02915744	Melisko, Michelle	A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With Anthracycline, A Taxane, and Capecitabine	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
> Breast > Breast Cancer Treatment > Advanced Breast Cancer > Phase I					
167511	NCT02684032	Rugo, Hope	Phase 1B Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination With Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
16758	NCT01676753	Chien, Jo	A Phase 1b trial of the cyclin-dependent kinase inhibitor dinaciclib in combination with pembrolizumab in patients with advanced breast cancer and assessment of MYC oncogene overexpression	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
> Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Neoadjuvant					
097517	NCT01042379	Chien, Jo	I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2)	Treatment	Julia Lyandres; julia.lyandres@ucsfmedctr.org; +1 415-885-7331 Sarah Davis; sarah.davis@ucsfmedctr.org; +1 415-885-7490
> Cutaneous > Melanoma > Immunotherapy > Immunotherapy Naïve					
17854	NCT03396952	Daud, Adil	Prostaglandin Inhibition and PD-1/CTLA4 blockade in Melanoma	Treatment	Ann Tittiger; Ann.Tittiger@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Cutaneous > Melanoma > Immunotherapy > Prior Immunotherapy					
16702	NCT02655822	Fong, Lawrence	A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 Treatment as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Katrina Sadang; katrinagrace.sadang@ucsf.edu;
16707	NCT02812875	Daud, Adil	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Cutaneous > Melanoma > Molecularly Targeted > BRAF/MEK Inhibitor Naïve > BRAF+					
CTSUS-1320	NCT02199730	Algazi, Alain	A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma	Treatment	Lawrence Chen; lawrence.chen@ucsf.edu;
> Cutaneous > Melanoma > Molecularly Targeted > Prior BRAF/MEK Inhibitor > BRAF/NRAS wild type					
14859	NCT02587650	Daud, Adil	Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma	Treatment	Ari Oglesby; arielle.oglesby@ucsf.edu;
> Gastrointestinal > Neuroendocrine Tumors (NET)					
16955	NCT02709889	Aggarwal, Rahul	An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3- Expressing Advanced Solid Tumors	Treatment	
> Gastrointestinal > Neuroendocrine Tumors (NET) > High Grade / Poorly Differentiated Neuroendocrine Carcinoma					
16955	NCT02709889	Aggarwal, Rahul	An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3- Expressing Advanced Solid Tumors	Treatment	
> Gastrointestinal > Anal Cancer > Prevention / Dysplasia					
AMC-A01	NCT02135419	Palefsky, Joel	ANCHOR Study: Anal Cancer Prevention Anal Cancer /HSIL Outcomes Research Study	Prevention	Abigail Arons; Abigail.Arons@ucsf.edu;
> Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced					
16708	NCT03132792	Kelley, Robin	A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRS Specific for Alpha-Fetoprotein (AFPC332T)in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC)	Treatment	Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Gastrointestinal > Rectal Cancer > Resectable > Neoadjuvant (before surgery)					
CTSUS-NCCTG-N1048	NCT01515787	Venook, Alan	A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	Treatment	Sharvina Ziyeh; ZiyehS@ucsf.edu; +1 415-353-7683

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Gastrointestinal > Pancreatic Cancer > Metastatic > First-Line					
164518	NCT02715804	Ko, Andrew	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Treatment	
> Gastrointestinal > Anal Cancer > Localized > HIV Positive					
167010	NCT02595866	Wang, Chia-Ching	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Paul Couey; Paul.Couey@ucsf.edu; +1 415-476-9554 ext. 315
> Gastrointestinal > Pancreatic Cancer > Metastatic > First-Line					
17709	NCT03214250	Ko, Andrew	Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together with Gemcitabine and nab-Paclitaxel with or without PD-1 Blocking Antibody (Nivolumab) in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma	Treatment	Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Resectable > Adjuvant (after surgery)					
16459	NCT02743494	Ko, Andrew	A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer	Treatment	Jennifer Luan; jennifer.luan@ucsf.edu; +1 415-514-6220
> Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced > Second-Line and Beyond					
16451	NCT02519348	Kelley, Robin	A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma	Treatment	Ariceli Alfaro; Ariceli.Alfaro@ucsf.edu;
16452	NCT02602327	Fidelman, Nicholas	Phase I/II Study of TAS-102 and Radioembolization with 90Y Resin Microspheres for Chemo-Refractory Colorectal Hepatic Metastases	Treatment	Curt Johanson; Curt.Johanson@ucsf.edu; +1 415-353-2310 Madeline Griffith; madeline.griffith@ucsf.edu;
17451	NCT02989857	Kelley, Robin	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	Treatment	
154524	NCT02703714	Kelley, Robin	Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers	Treatment	Madeline Griffith; madeline.griffith@ucsf.edu;
15452	NCT02150967	Kelley, Robin	A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations who Failed or are Intolerant to Platinum-based Chemotherapy	Treatment	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Gastrointestinal > Neuroendocrine Tumors (NET) > High Grade / Poorly Differentiated Neuroendocrine Carcinoma > Metastatic / Unresectable					
17459		Fidelman, Nicholas	Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A phase 2 randomized multicenter trial to compare hepatic progression-free survival following bland embolization, lipiodol chemoembolization, and drug-eluting bead chemoembolization of neuroendocrine liver metastases	Treatment	
> Gastrointestinal > Neuroendocrine Tumors (NET) > High Grade / Poorly Differentiated Neuroendocrine Carcinoma > Metastatic / Unresectable > Systemic Therapy - Second Line and Beyond					
17455	NCT03197012	Hope, Thomas	Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor	Treatment	
> Gastrointestinal > Neuroendocrine Tumors (NET) > Well-Differentiated Neuroendocrine Tumor > Carcinoid > Metastatic / Unresectable > Liver-Directed Therapy					
17705	NCT03457948	Fidelman, Nicholas	A pilot study of pembrolizumab and liver-directed therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive liver metastases	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
17705	NCT03457948	Fidelman, Nicholas	A pilot study of pembrolizumab and liver-directed therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive liver metastases	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Genitourinary > Prostate Cancer					
16955	NCT02709889	Aggarwal, Rahul	An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors	Treatment	
> Genitourinary > Bladder Cancer > Localized / Non-Muscle Invasive					
14524	NCT02451423	Fong, Lawrence	A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects with Non-Metastatic Transitional Cell Carcinoma of the Bladder	Treatment	Lani Bradish; landi.bradish@ucsf.edu; Paula Dutton; Paula.Dutton@ucsf.edu; +1 415-885-7871
> Genitourinary > Prostate Cancer > Non-Metastatic Castration Sensitive (Rising PSA)					
165514	NCT02981368	Carroll, Peter	A PrOspective Phase 2/3 Multi-Center, Open-Label Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer: Examination of Diagnostic Accuracy (OSPREDY)	Diagnostic	
> Genitourinary > Prostate Cancer > Localized					
RTOG-0924	NCT01368588	Roach, Mack	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial	Treatment	Ashley Wu; ashley.wu@ucsf.edu; +1 415-476-2651

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Genitourinary > Bladder Cancer > Localized / Muscle Invasive					
14524	NCT02451423	Fong, Lawrence	A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects with Non-Metastatic Transitional Cell Carcinoma of the Bladder	Treatment	Lani Bradish; landi.bradish@ucsf.edu; Paula Dutton; Paula.Dutton@ucsf.edu; +1 415-885-7871
> Genitourinary > Prostate Cancer > Metastatic Castration Sensitive					
16703	NCT03007732	Fong, Lawrence	Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination with Intratumoral SD-101 Therapy in Patients with Hormone-Naïve Oligometastatic Prostate Cancer Receiving Definitive Prostatic Radiation and Intermittent Androgen Deprivation Therapy	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Christopher Wong; christopher.wong@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Genitourinary > Renal Cell Carcinoma > Second Line					
16702	NCT02655822	Fong, Lawrence	A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Katrina Sadang; katrinagrace.sadang@ucsf.edu;
> Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC)					
145512	NCT02391025	Aggarwal, Rahul	Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate Cancer	Diagnostic	Kenneth Gao; kenneth.gao@ucsf.edu;
16952	NCT02711956	Aggarwal, Rahul	A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer	Treatment	Emily Chang; Emily.Chang3@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Phu Lam; Phu.Lam@ucsf.edu;
15559	NCT02911467	Aggarwal, Rahul	Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) as a Predictive Biomarker of Response in Castration-Resistant Prostate Cancer	Diagnostic	Christopher Sotto; Christopher.sotto@mrsc.ucsf.edu ;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
149510	NCT02262910	Fong, Lawrence	A Phase 1 Study of ES414 in Patients with Metastatic Castration-Resistant Prostate Cancer	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Gonzalo Choque; Gonzalo.Choque@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Nicole Zona; ZonaN@cc.ucsf.edu; Paula Dutton; Paula.Dutton@ucsf.edu; +1 415-885-7871 Rebecca Cook; Rebecca.Cook@ucsf.edu; +1 415-885-7329 ext. 7622
> Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Naïve					
12557	NCT01804465	Fong, Lawrence	A Randomized Phase 2 Trial of Immediate versus Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
> Genitourinary > Prostate Cancer > Localized > Pre-Therapy / Neoadjuvant					
16559	NCT02919111	Hope, Thomas	Gallium-68 PSMA-11 PET in intermediate to high-risk preprostatectomy patients	Diagnostic	
165514	NCT02981368	Carroll, Peter	A Prospective Phase 2/3 Multi-Center, Open-Label Study of 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer: Examination of Diagnostic Accuracy (OSPREY)	Diagnostic	
15557	NCT02526368	Aggarwal, Rahul	A Pilot Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer	Diagnostic	Christopher Sotto; Christopher.sotto@musc.ucsf.edu ;
14559	NCT02506114	Fong, Lawrence	An Open Label, Randomized Phase 2 Trial of Prostavac and Ipilimumab as Monotherapy or in Combination for Men with Localized Prostate Cancer Undergoing Radical Prostatectomy	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
> Genitourinary > Renal Cell Carcinoma > Second Line > Post TKI					
16707	NCT02812875	Daud, Adil	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant					
12557	NCT01804465	Fong, Lawrence	A Randomized Phase 2 Trial of Immediate versus Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy	Treatment	Lani Bradish; landi.bradish@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Genitourinary > Bladder Cancer > Metastatic > Prior Chemotherapy					
16709	NCT03007719	Fong, Lawrence	Functional Imaging of T-cell Activation with [18F]F-AraG in Bladder Cancer Patients Receiving Neoadjuvant or Standard of Care Atezolizumab	Diagnostic	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Katrina Sadang; katrinagrace.sadang@ucsf.edu;
16707	NCT02812875	Daud, Adil	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Genitourinary > Bladder Cancer > Localized / Non-Muscle Invasive > Prior BCG					
CIRB-SWOG-1605	NCT02844816	Porten, Sima	Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
16709	NCT03007719	Fong, Lawrence	Functional Imaging of T-cell Activation with [18F]F-AraG in Bladder Cancer Patients Receiving Neoadjuvant or Standard of Care Atezolizumab	Diagnostic	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Katrina Sadang; katrinagrace.sadang@ucsf.edu;
> Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant					
145515	NCT02494921	Aggarwal, Rahul	A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer	Treatment	Lani Bradish; landi.bradish@ucsf.edu; Paula Dutton; Paula.Dutton@ucsf.edu; +1 415-885-7871
> Gynecological > Cervix					
167010	NCT02595866	Wang, Chia-Ching	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Paul Couey; Paul.Couey@ucsf.edu; +1 415-476-9554 ext. 315

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Gynecological > Corpus/Endometrial					
159520	NCT02646748	Munster, Pamela	A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors	Treatment	Claire Hooker; claire.hooker@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
> Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > BRCA					
17401	NCT02855944	Chen, Lee-may	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr Trial): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Treatment	Kimberly Silverio; Kimberly.Silverio@ucsf.edu;
> Gynecological > Cervix > Maintenance					
GOG-3009	NCT02853604	Ueda, Stefanie	A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV	Treatment	Kimberly Silverio; Kimberly.Silverio@ucsf.edu;
> Head and Neck > Thyroid					
16955	NCT02709889	Aggarwal, Rahul	An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3- Expressing Advanced Solid Tumors	Treatment	
> Head and Neck > Nasopharyngeal					
CTSU-NRG-HN001	NCT02135042	Yom, Sue	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Treatment	Carter Hultman; carter.hultman@ucsf.edu; Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; +1 415-353-4294
152010	NCT02578641	Algazi, Alain	A Multicenter, Randomized, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr Virus-specific Autologous Cytotoxic T-Lymphocytes versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Kyusun Cha; kyun.cha@ucsf.edu;
> Head and Neck > Basal Cell Carcinoma > Locally Advanced					
122011	NCT01835626	Yom, Sue	A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck	Treatment	Carter Hultman; carter.hultman@ucsf.edu;
> Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Nasopharyngeal Carcinoma (NPC)					
162010	NCT03267498	Yom, Sue	Nivolumab in Combination with Chemoradiation for Patients with Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study with Correlative Biomarkers	Treatment	Carter Hultman; carter.hultman@ucsf.edu;
CTSU-NRG-HN001	NCT02135042	Yom, Sue	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Treatment	Carter Hultman; carter.hultman@ucsf.edu; Romobia Hutchinson; Romobia.Hutchinson@ucsf.edu; +1 415-353-4294

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
16203	NCT02611960	Algazi, Alain	A Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)	Treatment	Kyusun Cha; kyusun.cha@ucsf.edu;
> Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy					
17209	NCT03040999	Yom, Sue	A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)	Treatment	Kyusun Cha; kyusun.cha@ucsf.edu;
> Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Metastatic > All others					
16205	NCT02499328	Algazi, Alain	A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	Treatment	Carter Hultman; carter.hultman@ucsf.edu;
17204	NCT02521870	Algazi, Alain	A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Treatment	Carter Hultman; carter.hultman@ucsf.edu;
16707	NCT02812875	Daud, Adil	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy > Peri Operative					
16201	NCT03153982	Ryan, William	Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition with Ruxolitinib in Operable Head and Neck Cancer: A Window Trial	Treatment	Carter Hultman; carter.hultman@ucsf.edu;
> Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Positive					
167010	NCT02595866	Wang, Chia-Ching	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Paul Couey; Paul.Couey@ucsf.edu; +1 415-476-9554 ext. 315
> Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
15254	NCT02431208	Wong, Sandy	A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-8722;PD-L1 Antibody) Alone or in Combination with an Immunomodulatory Drug and/or Daratumumab in Patients with Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
139511	NCT02332850	Martin, Tom	A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
16707	NCT02812875	Daud, Adil	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
139510	NCT02109627	Andreadis, Charalambos	Phase Ib Study of Ficlaturzumab with High Dose Cytarabine in Relapsed and Refractory AML	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
> Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 3 or More Prior Lines of Therapy					
177016	NCT03361748	Shah, Nina	A PHASE 2, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA	Treatment	Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory					
167014	NCT02631044	Andreadis, Charalambos	A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
152516	NCT02440685	Kaplan, Lawrence	A PHASE 1/2, OPEN-LABEL, UNCONTROLLED, MULTIPLE-DOSE ESCALATION, COHORT EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF ASN002 IN RELAPSED/REFRACTORY LYMPHOMA, MYELOFIBROSIS, CHRONIC LYMPHOCYTIC LEUKEMIA AND ADVANCED SOLID TUMORS	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
> Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 3 or More Prior Lines of Therapy					
17704	NCT03274219	Shah, Nina	A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
> Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Untreated > Indolent					
112516	NCT01902225	Aj, Weiyun	A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination with Doxorubicin HCl Liposomal (or Doxil®) for the Treatment of Adults with Relapsed or Refractory T-cell Lymphomas	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
> Multiple / Ill-Defined Disease Sites > Solid Tumors					
159516	NCT02620839	Munster, Pamela	A Phase Ib, Open-Label Study of Alpelisib (BYL719) in Combination with Cisplatin in Patients with HPV+ Solid Tumor Malignancies	Treatment	Ann Chan; ann.chan@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
AMC-095	NCT02408861	Wang, Chia-Ching	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors	Treatment	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
16955	NCT02709889	Aggarwal, Rahul	An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3- Expressing Advanced Solid Tumors	Treatment	
16954	NCT02762981	Munster, Pamela	Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors	Treatment	Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Kathleen Comerford; kathleen.comerford@ucsf.edu;
167010	NCT02595866	Wang, Chia-Ching	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Paul Couey; Paul.Couey@ucsf.edu; +1 415-476-9554 ext. 315
15956	NCT02367196	Munster, Pamela	A Phase 1, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed against CD47, in Subjects with Advanced Solid and Hematologic Cancers	Treatment	Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Roshun Rahimi; roshun.rahimi@ucsf.edu;
159520	NCT02646748	Munster, Pamela	A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors	Treatment	Claire Hooker; claire.hooker@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
159518	NCT02556463	Munster, Pamela	A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid Tumors	Treatment	Armand Harb; Armand.Harb@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
159517	NCT02913131	Aggarwal, Rahul	Hyperpolarized C-13 Pyruvate as a Biomarker of PI3K/mTOR Pathway Inhibition in Patients with Advanced Solid Tumor Malignancies	Diagnostic	Emily Boyd; emily.boyd2@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337

> Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 2 (Low Grade)

131012	NCT02023905	Clarke, Jennifer	PI3K/mTOR Pathway Activation-Stratified Phase II Study of RAD001 (Everolimus) with and without Temozolomide in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma	Treatment	
--------	-------------	------------------	---	-----------	--

> Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 3 (Anaplastic)

161011	NCT02796261	Butowski, Nicholas	A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy	Treatment	
--------	-------------	--------------------	---	-----------	--

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Thoracic > Non-small cell Lung Cancer					
159520	NCT02646748	Munster, Pamela	A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors	Treatment	Claire Hooker; claire.hooker@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
16702	NCT02655822	Fong, Lawrence	A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu; Katrina Sadang; katrinagrace.sadang@ucsf.edu;
> Thoracic > Small cell Lung Cancer					
159520	NCT02646748	Munster, Pamela	A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors	Treatment	Claire Hooker; claire.hooker@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
> Thoracic > Sarcoma					
156512	NCT02659020	Jahan, Thierry	A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel with or without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma	Treatment	Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
> Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable					
15658	NCT02568267	Blakely, Collin	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Treatment	Mayra Gonzalez; mayra.gonzalez@ucsf.edu; Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
> Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable > 2nd Line and Above					
166511	NCT02823990	Gubens, Matthew	Phase II Trial of TG4010 plus Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)	Treatment	
166518	NCT02954991	Blakely, Collin	A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer	Treatment	
16707	NCT02812875	Daud, Adil	A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Jeremy Burbanks-Ivey; Jeremy.Burbanks-Ivey@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
> Other Trials					
10082	NCT01200017	Cowan, Morton	An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Treatment Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients		
117515	NCT01570998	Alvarado, Michael	A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288 Stig Kreps; Stig.Kreps@ucsfmedctr.org;
12088	NCT01583842	Matthay, Katherine	124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients with Neuroblastoma: A Pilot Study	Diagnostic	Pediatric Oncology; ; Varsha Shenoy; varsha.shenoy@ucsf.edu;
13106	NCT99999999	Chang, Susan	Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients with Gliomas	Diagnostic	
13108	NCT02022644	Butowski, Nicholas	A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging with Gadolinium In Patients with Recurrent High Grade Glioma	Treatment	Karishma Kumar; karishma.kumar@ucsf.edu;
135512	NCT02435472	Chan, June	A Randomized Clinical Trial of Supervised Exercise versus Usual Care Among Men Opting for Active Surveillance for Prostate Cancer (AS Exercise RCT)	Treatment	Sarah Joost; Sarah.Joost@ucsf.edu; +1 415-353-7349
13802	NCT01833806	Bucknor, Matthew	A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain	Supportive Care	
14083	NCT02124772	Mueller, Sabine	An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations	Treatment	Jasmin To-Hutyra; Jasmin.To@ucsf.edu; Lajhem Cambridge; lajhem.cambridge@ucsf.edu;
14251	NCT02187133	Andreadis, Charalambos	A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory non-Hodgkin Lymphoma	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
14402	NCT02270021	Moscicki, Anna-Barbar	Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women	Other	
144524	NCT02081755	Hirose, Ryutaro	A 36 month multi-center, open label, randomized, comparator study to evaluate the efficacy and safety of everolimus immunosuppression treatment in liver transplantation for hepatocellular carcinoma exceeding Milan criteria	Treatment	
14557	NCT02451345	Carroll, Peter	A Decision-Support Tool for Men with Prostate Cancer - Clinical & Lifestyle Study	Other	
150812	NCT02962167	Mueller, Sabine	PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)	Treatment	Shelby Gripe; shelby.gripe@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
150818	NCT02425904	Hermiston, Michelle	Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
150819	NCT02960230	Mueller, Sabine	H3.3K27M Specific Peptide Vaccine Combined with Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as Other Newly Diagnosed HLA-A2+ H3.3K27M Positive Gliomas	Treatment	Sharon Kresge; leess@peds.ucsf.edu; +1 415-514-3658 Shelby Gripe; shelby.gripe@ucsf.edu;
151011	NCT02481154	Clarke, Jennifer	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation	Treatment	
151013	NCT03335280	Evans, Michael	A Feasibility Study of Gallium-68 Citrate PET to Detect Hyperactive mTOR Activity in Glioma	Diagnostic	
15103	NCT02549833	Taylor, Jennie	Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients with WHO Grade II Glioma	Treatment	
15108	NCT02924038	Butowski, Nicholas	Pilot Randomized Neo-Adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine plus Poly-ICLC in Patients with WHO Grade II Low-Grade Glioma (LGG)	Treatment	Ashley De Silva; Ashley.DeSilva@ucsf.edu; +1 415-353-2653 Jennifer Ayran; Jennifer.Ayran@ucsf.edu; +1 415-885-3704 Thelma Munoz; Thelma.Munoz@ucsf.edu; +1 415-353-2523
15109	NCT02526017	Fong, Lawrence; Butowski, Nicholas	A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers	Treatment	
152511	NCT02614066	Logan, Aaron	A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
152514	NCT02253316	Martin, Tom	A Phase II Study of IRD (Ixazomib, Lenalidomide, and Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
154521	NCT0	Aparici, Carina	Gallium-68 Citrate PET to Detect MYC Amplification and Transferring Receptor Expression in Hepatocellular Carcinoma (HCC)	Diagnostic	
155510	NCT02613273	Kenfield, Stacey	A Clinical Trial of High-Intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer	Supportive Care	
155513		Carroll, Peter	A Randomized Controlled Clinical Trial of a Smartphone-Based App to Improve Urinary and Sexual Function Outcomes after Robot-Assisted Laparoscopic Radical Prostatectomy Surgery	Supportive Care	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
155518	NCT02735252	Aggarwal, Rahul	Precision Oncology and Molecular Targeting in Advanced Prostate Cancer: Identifying Predictive Markers of Response (The "PROMOTE" Study)	Basic Science	Lani Bradish; landi.bradish@ucsf.edu;
15632		Herbst, Ellen	Mobile Technology to Improve Treatment Engagement and Outcomes in Smokers with Post-Traumatic Stress Disorder:Pilot	Other	
15657	NCT02219711	Blakely, Collin	A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies	Treatment	Hien Do; hien.do@ucsf.edu; Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
157521	NCT03095352	Rugo, Hope	A Randomized Phase II Study of Pembrolizumab, an anti-PD(programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
15989		Porten, Sima	Preoperative Guided Imagery in Patients Undergoing Urology Surgery	Supportive Care	
15991	NCT02442635	Dhruva, Anand	Developing a Yoga Intervention During Cancer Chemotherapy	Supportive Care	
16081	NCT02650401	Sabnis, Amit	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions	Treatment	Holly Chen; holly.chen@ucsf.edu;
160816	NCT03086616	Mueller, Sabine	PNOC009: A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging with Gadolinium in Children with Diffuse Intrinsic Pontine Glioma	Treatment	
16082	NCT02332668	Vo, Kieuhoa	A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)	Treatment	Holly Chen; holly.chen@ucsf.edu; Pediatric Oncology; ;
160821	NCT03139331	Vo, Kieuhoa	Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma	Treatment	Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
160823	NCT01690520	Willert, Jennifer	Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off-the-shelf ex vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies	Treatment	Ying Lu; Ying.Lu@ucsf.edu;
160829	NCT02909777	Vo, Kieuhoa	Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma	Treatment	Holly Chen; holly.chen@ucsf.edu;
160830	NCT02670525	Loh, Mignon	Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias	Basic Science	Anna Garzon; anna.garzon@ucsf.edu; Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
16088	NCT02947373	Mueller, Sabine	Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children with Brain Tumors	Diagnostic	Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
161013	NCT02858895	Butowski, Nicholas	An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent or Progressive Glioblastoma	Treatment	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
161015	NCT02871843	Butowski, Nicholas	G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas with Intact 1p/19q Chromosomes	Treatment	
161019	NCT02981940	Taylor, Jennie	Ivy Foundation Early Phase Clinical Trials Consortium: A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma	Treatment	
16104	NCT02667587	Taylor, Jennie	A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma	Treatment	
16105	NCT99999999	Taylor, Jennie	Neurocognitive and Quality of Life Assessment in Patients with Brain Tumors	Other	
16106	NCT02783495	Taylor, Jennie	Feasibility and Efficacy of an iPad-Based Cognitive Rehabilitation Program in Brain Tumor Patients	Supportive Care	
16107	NCT02414165	Butowski, Nicholas	A Phase 2/3 Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma	Treatment	
16109	NCT02844439	Butowski, Nicholas	A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma	Treatment	
16251	NCT02776891	Evans, Michael	A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma	Diagnostic	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
164511	NCT02965521	Van Blarigan, Erin	Survivor Choices for Eating and Drinking (SUCCEED) ? Colorectal Cancer	Other	
164514	NCT02174549	Fidelman, Nicholas	PHASE I DOSE-ESCALATING STUDY OF COMBINING TIRAPAZAMINE AND TRANSARTERIAL EMBOLIZATION (TAE) IN HEPATOCELLULAR CARCINOMA AND ADVANCED SOLID TUMORS	Treatment	
16527	NCT02872714	Friedlander, Terence	A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
165513	NCT03009981	Aggarwal, Rahul	A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
16552	NCT02814669	Fong, Lawrence	A Phase 1b, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have Progressed Following Treatment with an Androgen Pathway Inhibitor	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
16557	NCT03248570	Fong, Lawrence	Phase 2 open label study of pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC) with or without DNA damage repair defects	Treatment	Lani Bradish; landi.bradish@ucsf.edu;
166512	NCT03087448	Blakely, Collin	A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive NSCLC	Treatment	Emily Houlihan; Emily.Houlihan@ucsf.edu; +1 415-353-7143 Linsey Curran; linsey.curran@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
166520	NCT03217071	Yom, Sue	PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer with Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study with Correlative Biomarkers	Treatment	Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
166521	NCT03232892	Blakely, Collin	Phase II trial to evaluate trametinib in patients with advanced NF1-mutant non-small cell lung cancer	Treatment	Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
167012	NCT02897765	Friedlander, Terence	An Open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
16751	NCT03011684	Rosen, Mitchell	Fertility Preservation using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial	Supportive Care	
16752	NCT02620852	Esserman, Laura	The WISDOM Study (Women Informed to Screen Depending on Measures of Risk)	Screening	
16801	NCT02897635	Dhruva, Anand	Developing an Integrative Ayurvedic Intervention for Breast Cancer Survivorship	Supportive Care	
16802	NCT03252145	Smoot, Betty	Treatment of breast cancer-related LE with a negative pressure device: a pilot randomized controlled study	Supportive Care	
16803	NCT03209440	Rabow, Michael	Dignity Therapy RCT led by Nurses or Chaplains for Elderly Cancer Outpatients	Supportive Care	
16855	NCT02318277	Algazi, Alain	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors	Treatment	Melinda Lem; melinda.lem@ucsf.edu;
169513	NCT02723006	Tsai, Katy	An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma	Treatment	Erika Zigman; erika.zigman@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
169514	NCT02608125	Aggarwal, Rahul	A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations	Treatment	Ann Chan; ann.chan@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
169516	NCT02900651	Munster, Pamela	A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Treatment	Emily Boyd; emily.boyd2@ucsf.edu;
169517	NCT02908451	Ko, Andrew	A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer	Treatment	Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Phu Lam; Phu.Lam@ucsf.edu;
169518	NCT02595931	Aggarwal, Rahul	Phase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors	Treatment	Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Phu Lam; Phu.Lam@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
169519	NCT02498613	Munster, Pamela	A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors	Treatment	Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Kathleen Comerford; kathleen.comerford@ucsf.edu;
169521	NCT03318445	Munster, Pamela	Combination therapy of Rucaparib and Irinotecan in cancers with DNA repair mutations	Treatment	Armand Harb; Armand.Harb@ucsf.edu;
169522	NCT03194685	Smith, Catherine	A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia	Treatment	
169524	NCT03136055	Bergsland, Emily	A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas	Treatment	Claire Hooker; claire.hooker@ucsf.edu; Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337
16953	NCT02670044	Olin, Rebecca	A Phase Ib/II Multi-Arm Study with Venetoclax in Combination with Cobimetinib and Venetoclax in Combination with Idasanutlin in Patients Aged >= 60 Years with Relapsed or Refractory Acute Myeloid Leukemia who are not Eligible for Cytotoxic Therapy	Treatment	
16957	NCT02657889	Munster, Pamela	Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer	Treatment	Kamran Abri Lavasani; Kamran.AbriLavasani@ucsf.edu; +1 415-353-8337 Roshun Rahimi; roshun.rahimi@ucsf.edu;
170817	NCT00000000	Mueller, Sabine	PNOC015: An Open Label Single Arm Phase I/II study of MTX110 delivered by convection-enhanced delivery (CED) in patients with diffuse intrinsic pontine glioma (DIPG) previously treated with external beam radiation therapy	Treatment	
170819	NCT03330197	Mueller, Sabine	A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veldimex in Pediatric Brain Tumor Subjects	Treatment	
171016	NCT02571036	Butowski, Nicholas	A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies	Treatment	
17107	NCT02658279	Clarke, Jennifer	A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype	Treatment	
172016	NCT03463889	Hope, Thomas	Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET for Imaging of Thyroid Cancer: A Feasibility Study	Diagnostic	
17254	NCT02959944	Logan, Aaron	A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
174017		Ohliger, Michael	Gallium-68 Prostate Specific Membrane Antigen for Ovarian Cancer: A Pilot Feasibility Study	Diagnostic	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
17403	NCT03038100	Chen, Lee-may	A Phase III, Multi-center, Randomized Study of Atezolizumab versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly Diagnosed Stage III or State IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Treatment	
17404	NCT02715284	Chen, Lee-may	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors	Treatment	
174512	NCT03193190	Ko, Andrew	A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER)	Treatment	
174517	NCT03396926	Atreya, Chloe	Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer	Treatment	
174518	NCT99999999	Behr, Spencer	Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET in Hepatocellular Carcinoma (HCC); a feasibility study	Diagnostic	
174519	NCT03174444	Nguyen, Tung	Small Media Interventions to Increase Colorectal Cancer Screening among Chinese Americans	Screening	
174523	NCT03439891	Kelley, Robin	Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy	Treatment	
174525		Van Blarigan, Erin	Self-Monitoring and Reminder Texts for Physical Activity After Cancer II (Smart Pace II)	Supportive Care	
174528	NCT03377361	Atreya, Chloe	A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers	Treatment	
174534	NCT03528863	Atreya, Chloe	Being Present 2.0: Web-based Mindfulness Meditation for Gastrointestinal Cancer Patients and Caregivers	Supportive Care	
17457	NCT02052778	Kelley, Robin	A Dose-Finding Phase 1 Study Of Tas-120 In Patients With Advanced Solid Tumors With Or Without Fibroblast Growth Factor/Receptor (Fgf/Fgfr)-Related Abnormalities Followed By A Phase 2 Study In Patients With Advanced Solid Tumors With Fgf/Fgfr-Related Abnormalities	Treatment	
17527	NCT03427476	Behr, Spencer	CTT1057, a Small Molecular Inhibitor of Prostate Specific Membrane Antigen (PSMA), as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma: A Pilot Study	Diagnostic	
175511	NCT02531516	Feng, Felix	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy	Treatment	
175513		Kenfield, Stacey	A Randomized Clinical Trial of Lifestyle Interventions using Digital Health Technology and Coaching Versus Usual Care among Men with Prostate Cancer II (Prostate 8 - II)	Prevention	
175518	NCT03353740	Hope, Thomas	Gallium-68 PSMA-11 PET in patients with biochemical recurrence	Diagnostic	
17556	NCT02975934	Aggarwal, Rahul	A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	Treatment	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
17631		Wang, Julie	Cigarette Reduction with the Quitbit Lighter & Mobile App for Smoking Cessation: A Randomized Controlled Trial	Diagnostic	
17651	NCT02709512	Jahan, Thierry	Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Treatment	Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
176513	NCT03311672	Franc, Benjamin	T-Cell PET Imaging with [18F]F-AraG and Radiomics to Guide Combined Radiation and Systemic Immune Modulating Therapies	Diagnostic	Dora Tao; dora.tao@ucsf.edu;
176518	NCT03318939	Blakely, Collin	A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)	Treatment	Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
17652	NCT02917993	Blakely, Collin	An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Treatment	Rosa Paz; Rosa.Paz@ucsf.edu; +1 415-885-7329
17701	NCT03165994	Ko, Andrew	A Pilot Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers	Treatment	Julie McCluggage; Julie.McCluggage@ucsf.edu;
17707	NCT02731729	Tsai, Katy	A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab plus Nivolumab in Patients with Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy	Treatment	Andrew Chon; andrew.chon@ucsf.edu; Julie McCluggage; Julie.McCluggage@ucsf.edu;
177514	NCT01969643	Rugo, Hope	A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
177528	NCT02947685	Chien, Jo	A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer	Treatment	Amy Deluca; Amy.Deluca@ucsf.edu; +1 415-353-7288
177543	NCT03006913	Pasick, Rena	Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients	Prevention	
17951	NCT02097810	Munster, Pamela	A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB (RXDX-101) IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NTRK3, ROS1, OR ALK MOLECULAR ALTERATIONS	Treatment	Claire Hooker; claire.hooker@ucsf.edu;
17953	NCT03076372	Munster, Pamela	A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors	Treatment	
17957	NCT03379584	Martin, Tom	A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma	Treatment	
AALL1331	NCT02101853	Loh, Mignon	Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	Treatment	Anna Garzon; anna.garzon@ucsf.edu;
AALL1521	NCT02723994	Loh, Mignon	A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Anna Garzon; anna.garzon@ucsf.edu;

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
AALL15P1	NCT02828358	Loh, Mignon	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Anna Garzon; anna.garzon@ucsf.edu;
AALL1631	NCT03007147	Loh, Mignon	International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones	Treatment	Anna Garzon; anna.garzon@ucsf.edu;
AAML1331	NCT02339740	Braun, Benjamin	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All- Trans Retinoic Acid	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
AAML1531	NCT02521493	Huang, Benjamin	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome A COG Groupwide Phase III Study	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
ABTC-1301	NCT02133183	Clarke, Jennifer	Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients	Treatment	
ABTC-1602	NCT03216499	Clarke, Jennifer	Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma	Treatment	
ACNS1123	NCT01602666	Banerjee, Anu	Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)	Treatment	Pediatric Oncology; ;
ADVL1322	NCT01956669	Sabnis, Amit	A Phase II Trial of Pazopanib NSC# 737754, IND# 65747 in Children with Refractory Solid Tumors	Treatment	Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
ADVL1414	NCT02323880	Vo, Kieuhoa	A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors	Treatment	Holly Chen; holly.chen@ucsf.edu;
ADVL1416	NCT02564198	Vo, Kieuhoa	A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors	Treatment	Holly Chen; holly.chen@ucsf.edu; Pediatric Oncology; ;
ADVL1513	NCT02780804	Vo, Kieuhoa	A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	Treatment	Holly Chen; holly.chen@ucsf.edu;
ADVL1515	NCT02808650	Vo, Kieuhoa	A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors	Treatment	Holly Chen; holly.chen@ucsf.edu;
ADVL1521	NCT03190915	Stieglitz, Elliot	A Phase 2 study of the MEK inhibitor Trametinib (IND#119346, NSC#763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia	Treatment	Anna Garzon; anna.garzon@ucsf.edu;
ALLIANCE-A051301	NCT02443077	Andreadis, Charalambos	A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype	Treatment	Jenai Wilmoth; Jenai.Wilmoth@ucsf.edu;
ALLIANCE-A071401	NCT02523014	Taylor, Jennie	Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations	Treatment	

UCSF Protocol No.	Clinicaltrials.gov Protocol No.	PI Name	Title	Protocol Type	Study Contact
AMC-088	NCT02059499	Jay, Naomi	A Randomized, Phase III Study of Intra-anal imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women	Treatment	
AMC-092	NCT02437851	Berry, Michael	A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons	Treatment	
ANHL1522	NCT02900976	Hermiston, Michelle	A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Anna Garzon; anna.garzon@ucsf.edu;
AOST1321	NCT02470091	Goldsby, Robert	Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma	Treatment	Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
APEC1621SC	NCT03155620	Goldsby, Robert	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol	Screening	
ARST1321	NCT02180867	Goldsby, Robert	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)	Treatment	Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
ARST1431	NCT02567435	Goldsby, Robert	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	Treatment	
BMT-CTN-1401	NCT02728102	Shah, Nina	Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions	Treatment	Julie McCluggage; Julie.McCluggage@ucsf.edu;
BMT-CTN-1506	NCT02997202	Damon, Lloyd	A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML	Treatment	
NANT-2011-04	NCT01711554	Matthay, Katherine	A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma	Treatment	Varsha Shenoy; varsha.shenoy@ucsf.edu;
NANT-2013-02	NCT02298348	Matthay, Katherine	A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients with Relapsed and Refractory Neuroblastoma	Treatment	Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;
TACL-2014-001	NCT01614197	Hermiston, Michelle	A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma	Treatment	Anna Garzon; anna.garzon@ucsf.edu; Fabienne Hollinger; Fabienne.Hollinger@ucsf.edu;